Lipid A controls the robustness of intratumoral accumulation of attenuated Salmonella in mice

International Journal of Cancer

Volumn 135, Issue 3, 2014, Pages 647-657

  Zhang, Miaomin ^a   Swofford, Charles A ^a   Forbes, Neil S ^a  

^a University of Massachusetts   (United States)

Author keywords

Drug production simulation; Inflammation; Lipid A; Salmonella; Tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; LIPID A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL STRAIN; BREAST CANCER; CONTROLLED STUDY; IMMUNOFLUORESCENCE; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SALMONELLA MINNESOTA; TUMOR VOLUME;

DRUG PRODUCTION SIMULATION; INFLAMMATION; LIPID A; SALMONELLA; TUMOR TARGETING;

ANIMALS; APOPTOSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LIPID A; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MODELS, THEORETICAL; SALMONELLA TYPHIMURIUM;

EID: 84901061055     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28700     Document Type: Article

References (41)

1. Forbes NS,. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 2010; 10: 785-94.
2. Leschner S, Weiss S,. Salmonella-allies in the fight against cancer. J Mol Med (Berlin, Germany) 2010; 88: 763-73.
3. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002; 20: 142-52.
4. Heimann DM, Rosenberg SA,. Continuous intravenous administration of live genetically modified Salmonella typhimurium in patients with metastatic melanoma. J. Immunother. 2003; 26: 179-80.
5. Nemunaitis J, Cunningham C, Senzer N, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 2003; 10: 737-44.
6. Pawelek JM, Low KB, Bermudes D,. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997; 57: 4537-44.
7. Forbes NS, Munn LL, Fukumura D, et al. Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res. 2003; 63: 5188-93.
8. Ganai S, Arenas RB, Forbes NS,. Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer 2009; 101: 1683-91.
9. Loeffler M, Le'Negrate G, Krajewska M, et al. Inhibition of tumor growth using Salmonella expressing Fas ligand. J Natl Cancer Inst 2008; 100: 1113-16.
10. Ryan RM, Green J, Williams PJ, et al. Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Ther. 2009; 16: 329-39.
11. Loeffler M, Le'Negrate G, Krajewska M, et al. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA 2007; 104: 12879-83.
12. Al-Ramadi BK, Fernandez-Cabezudo MJ, El-Hasasna H, et al. Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clin Immunol (Orlando, FL) 2009; 130: 89-97.
13. Yam C, Zhao M, Hayashi K, et al. Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res 2010; 164: 248-55.
14. Stein WD, Bates SE, Fojo T,. Intractable cancers: The many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr Drug Targets 2004; 5: 333-46.
15. Minchinton AI, Tannock IF,. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92.
16. Ganai S, Arenas RB, Sauer JP, et al. In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther 2011; 18: 457-66.
17. Kasinskas RW, Forbes NS,. Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng 2006; 94: 710-21.
18. Kasinskas RW, Forbes NS,. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res 2007; 67: 3201-9.
19. Toley BJ, Forbes NS,. Motility is critical for effective distribution and accumulation of bacteria in tumor tissue. Integr Biol (Camb) 2012; 4: 165-76.
20. Leschner S, Westphal K, Dietrich N, et al. Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS One 2009; 4: e6692.
21. Crull K, Bumann D, Weiss S,. Influence of infection route and virulence factors on colonization of solid tumors by Salmonella enterica serovar Typhimurium. FEMS Immunol Med Microbiol 2011; 62: 75-83.
22. Van Amersfoort ES, Van Berkel TJC, Kuiper J,. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003; 16: 379-414.
23. Lõpez-Bojõrquez LN, Dehesa AZ, Reyes-Terán G,. Molecular mechanisms involved in the pathogenesis of septic shock. Arch Med Res 2004; 35: 465-79.
24. Somerville JE, Jr, Cassiano L, Darveau RP,. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect Immun 1999; 67: 6583-90.
25. Khan SA, Everest P, Servos S, et al. A lethal role for lipid A in Salmonella infections. Mol Microbiol 1998; 29: 571-79.
26. Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 1999; 17: 37-41.
27. Clairmont C, Lee KC, Pike J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 2000; 181: 1996-2002.
28. Pawelek JM, Low KB, Bermudes D,. Bacteria as tumour-targeting vectors. Lancet Oncol 2003; 4: 548-56.
29. Thamm DH, Kurzman ID, King I, et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: Phase I evaluation. Clin Cancer Res 2005; 11: 4827-34.
30. Lee KC, Zheng LM, Luo X, et al. Comparative evaluation of the acute toxic effects in monkeys, pigs and mice of a genetically engineered Salmonella strain (VNP20009) being developed as an antitumor agent. Int J Toxicol 2000; 19: 19-25.
31. Copeland S, Warren HS, Lowry SF, et al Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immun 2005; 12: 60-7.
32. Kuhns DB, Alvord WG, Gallin JI,. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 1995; 171: 145-52.
33. Hasunuma R, Morita H, Tanaka S, et al. Differential clearance and induction of host responses by various administered or released lipopolysaccharides. J Endotoxin Res 2001; 7: 421-29.
34. Thurber GM, Weissleder R,. A systems approach for tumor pharmacokinetics. PLoS One 2011; 6: e24696.
35. Bagh S, Mazumder M, Velauthapillai T, et al. Plasmid-borne prokaryotic gene expression: Sources of variability and quantitative system characterization. Phys Rev E 2008; 77: 021919.
36. Venkatasubramanian R, Henson MA, Forbes NS,. Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies. J Theor Biol 2008; 253: 98-117.
37. Zhao M, Yang M, Li X-M, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005; 102: 755-60.
38. Trédan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441-54.
39. Vaupel P, Mayer A,. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-39.
40. Bermudes D, Low B, Pawelek J,. Tumor-targeted Salmonella-Highly selective delivery vectors. Cancer Gene Ther 2000; 465: 57-63.
41. Zanetti G, Heumann D, Gerain J, et al. Cytokine production after intravenous or peritoneal Gram-negative bacterial challenge in mice-Comparative protective efficacy of antibodies to tumor-necrosis-factor-alpha and to lipopolysaccharide. J Immunol 1992; 148: 1890-97.